Inhalation Sciences announces Redeye to initiate regular stock analysis monitoring of the company
(Stockholm, Sweden, 29 September, 2021) Inhalation Sciences AB (ISAB) announces today it has commissioned Redeye to produce regular, in-depth stock analyses of the company. The strategic goal is to increase ISAB’s market profile and visibility, enabling investors and stakeholders to develop a better understanding of the business and its performance and prospects.
Redeye specializes in providing analysis and insights into companies within the Nordic region’s fast-growing and innovative Life Science and Technology sector. Redeye’s first report on ISAB has now been published and is available on ISAB’s website, https://www.inhalation.se/investors/bolagsanalys/, and on Redeye's website, https://www.redeye.se/research/821547/inhalation-sciences-breathtaking-potential
For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.firstname.lastname@example.org Mobile: +46 (0)73 628 9153Press release in PDF format